Vaxart (OTCMKTS:VXRT) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Vaxart (OTCMKTS:VXRT) to a hold rating in a research report report published on Thursday,Zacks.com reports.

Vaxart Price Performance

Shares of VXRT stock traded down $0.00 during trading hours on Thursday, hitting $0.55. 331,273 shares of the company’s stock were exchanged, compared to its average volume of 314,656. The stock’s 50-day moving average is $0.61 and its 200-day moving average is $0.62. The stock has a market cap of $132.59 million, a price-to-earnings ratio of 3.64 and a beta of 1.09. Vaxart has a 52 week low of $0.30 and a 52 week high of $0.84.

Vaxart (OTCMKTS:VXRT) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share for the quarter, meeting the consensus estimate of $0.02. Vaxart had a net margin of 14.51% and a return on equity of 61.43%. The firm had revenue of $39.23 million during the quarter, compared to analysts’ expectations of $50.50 million. Equities research analysts forecast that Vaxart will post -0.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vaxart

Several hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new stake in Vaxart during the 2nd quarter worth about $794,000. Jones Financial Companies Lllp grew its holdings in Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 478,111 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of Vaxart during the 1st quarter valued at $31,000. Creative Planning acquired a new position in shares of Vaxart in the 2nd quarter valued at $33,000. Finally, Invesco Ltd. boosted its position in shares of Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 70,568 shares during the last quarter. Institutional investors own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.